SCHEMBL1817484

SCHEMBL1817484

COc1ccc(S(=O)(=O)Cl)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP1A1 P04798 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP1B1 Q16678 1/20 0.44
PKM P14618 2/20 0.43
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
CPS1 P31327 2/20 0.42
KAT6A Q92794 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30540030 1.00 TRPV4 (0.47) TRPV4SMN1; SMN2GAAMAPK1KMT2A
SCHEMBL14775287 0.85 SMN1; SMN2 (0.48) TRPV4SMN1; SMN2GAAMAPK1KMT2A
SCHEMBL29595784 0.85 SMN1; SMN2 (0.48) TRPV4SMN1; SMN2GAAMAPK1KMT2A
SCHEMBL19743928 0.81 PTGS2 (0.50) SMN1; SMN2GAAMAPK1KMT2ACYP1A1
SCHEMBL27949851 0.81 CYP1A1 (0.47) SMN1; SMN2GAAMAPK1KMT2ACYP1A1
SCHEMBL29503477 0.81 PTGS2 (0.50) SMN1; SMN2GAAMAPK1KMT2ACYP1A1
SCHEMBL27699833 0.81 SOS1 (0.47) SMN1; SMN2GAAMAPK1KMT2ACYP1A1
SCHEMBL30454604 0.81 KAT6A (0.41) TRPV4KMT2AALDH1A1MAPTCPS1
SCHEMBL16084901 0.81 KAT6A (0.41) TRPV4KMT2AALDH1A1MAPTCPS1
SCHEMBL24010102 0.80 SMN1; SMN2 (0.47) SMN1; SMN2GAAMAPK1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 CN claimed
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-20250152574-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-15 US disclosed
WO-2025085815-A1 PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION SEED THERAPEUTICS US, INC. (US) 2025-04-24 WO disclosed
WO-2025083472-A2 PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION SEED THERAPEUTICS US, INC. (US) 2025-04-24 WO disclosed
CN-119731156-A Emopanamide binding protein inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-03-28 CN disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-20140288070-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-09-25 US disclosed
US-20140288070-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-09-25 US disclosed
WO-2014060432-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, S.A. (ES) 2014-04-24 WO disclosed
US-8673928-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2014-03-18 US disclosed
US-8673928-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2014-03-18 US disclosed
US-20110212918-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110152258-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON INC. 2011-06-23 US disclosed
US-20110152258-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON INC. 2011-06-23 US disclosed
WO-2011063159-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-26 WO disclosed
WO-2011060199-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS TRPV4 3761/4885SMN1; SMN2 3085/4885GAA 2533/4885
US-20110212918-A1 BORON-CONTAINING SMALL MOLECULES BCL6B, BCL6, BTD TRPV4 2256/4885SMN1; SMN2 4069/4885GAA 536/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS TRPV4 3761/4885SMN1; SMN2 3085/4885GAA 2533/4885
US-20110152258-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, KRAS, RAF1 TRPV4 1206/4885SMN1; SMN2 3700/4885GAA 3303/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS TRPV4 3761/4885SMN1; SMN2 3085/4885GAA 2533/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD TRPV4 3686/4885SMN1; SMN2 3097/4885GAA 2625/4885
US-20140288070-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, KRAS, RAF1 TRPV4 1206/4885SMN1; SMN2 3700/4885GAA 3303/4885
US-20250152574-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP TRPV4 4560/4885SMN1; SMN2 1668/4885GAA 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.